Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 5/20 | 0.56 |
| ▸ | CA1 | P00915 | 4/20 | 0.52 |
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | NOS1 | P29475 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16980950 | 0.81 | NOS1 (0.53) | DHFRNOS1 | |
| SCHEMBL5790738 | 0.81 | DHFR (0.58) | DHFRCA1CA2CA9NOS1 | |
| SCHEMBL14169207 | 0.81 | CA1 (0.61) | DHFRCA1CA2CA9NOS1 | |
| SCHEMBL5549729 | 0.78 | DHFR (0.58) | DHFRCA1CA2CA9NOS1 | |
| SCHEMBL25837567 | 0.77 | DHFR (0.54) | DHFRCA1CA2CA9NOS1 | |
| SCHEMBL3745109 | 0.77 | DHFR (0.80) | DHFRCA1CA2CA9 | |
| SCHEMBL3740020 | 0.76 | DHFR (0.64) | DHFRCA1CA2CA9 | |
| SCHEMBL8813993 | 0.76 | NOS1 (0.61) | DHFRNOS1 | |
| SCHEMBL24845727 | 0.76 | CA1 (0.66) | DHFRCA1CA2CA9 | |
| SCHEMBL11634253 | 0.74 | CA1 (0.72) | DHFRCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2039683-B1 | Vasculostatic agents and methods of use thereof | TARGEGEN INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | TARGEGEN, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | TARGEGEN INC. | 2010-11-04 | — | — | US | disclosed |
| EP-2039683-A2 | Vasculostatic agents and methods of use thereof | Targegen, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. | 2007-09-06 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208493-B2 | Vasculostatic agents and methods of use thereof | TARGEGEN, INC. (US) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330030-A1 | Vasculostatic Agents and Methods of Use Thereof | RBP1, RBP4, VCAM1 | DHFR 1951/4885CA1 1394/4885CA2 2351/4885 |
| US-20070208019-A1 | Vasculostatic agents and methods of use thereof | RBP1, RBP4, VCAM1 | DHFR 1951/4885CA1 1394/4885CA2 2351/4885 |
| US-20100278811-A1 | VASCULOSTATIC AGENTS AND METHODS OF USE THEREOF | RBP1, RBP4, VCAM1 | DHFR 1951/4885CA1 1394/4885CA2 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.